Background and Purpose: This subgroup analysis from the Ticlopidine Aspirin Stroke Study (TASS) compared ticlopidine, a new antiplatelet agent, with aspirin for the prevention of recurrent transient ischemic attacks in patients who had a recent reversible cerebrovascular event.
ntiplatelet drugs have been investigated for the A prevention of cerebrovascular ischemic events including transient ischemic attacks (TIAs) and stroke for more than 20 years. Results from a metaanalysis of antiplatelet agents have shown that aspirin is effective for stroke prevention in patients with cerebral ischemia.' In the Canadian Cooperative Study Group, aspirin was superior to placebo for reducing the incidence of stroke in high-risk patients.2 Although the primary end point was stroke or death, a secondary end point analyzed and reported was TIA or other reversible ischemic events plus stroke or death. On the basis of the findings from this trial, aspirin was approved at a dose of 1300 mg/d for stroke prevention and the reduction of TIAs in men at risk for stroke. The benefits of aspirin for stroke prevention in women are still controversial.
Ticlopidine is a new antiplatelet agent that has been evaluated for the prevention of initial or recurrent stroke in patients at high risk for a cerebrovascular event. 3, 4 Although its exact mechanism of action is not fully elucidated, it is thought that ticlopidine inhibits adenosine diphosphate-induced platelet aggregation by altering the platelet membrane response to fibrinogenassociated thrombogenic stimuli.56 The Ticlopidine Aspirin Stroke Study (TASS) was a multicenter, randomized trial comparing ticlopidine and aspirin for the prevention of stroke in patients with a recent reversible cerebrovascular ischemic event on entry.3 Ticlopidine reduced the overall risk of nonfatal or fatal stroke by 21% and death or stroke by 12% compared with aspirin using an intent-to-treat analysis.
Before the initiation of TASS, tertiary end points were preselected for data collection and analysis in addition to the principal end points of death or stroke and fatal or nonfatal stroke and the secondary end points of nonfatal myocardial infarction and peripheral vascular disease. These "soft" end points included all reversible cerebrovascular ischemic events that occurred after randomization. Thus, both the eligibility criteria-reversible cerebral ischemic events-and the study end points in TASS and the Canadian aspirin trial were similar.
Examination of the effects of antiplatelet therapy on these reversible or soft end points is important because patients with reversible events are at high risk for stroke; the presence of these reversible events indicates the activity of an underlying disease process; and the occurrence of these events during daily life could, on For this analysis, the primary end point was the first occurrence of a reversible cerebrovascular ischemic event, either TIA, AF, or RIND. In a post hoc analysis, TIA, when it occurred alone, was established as a secondary end point. These end points were evaluated independently and when they occurred as a composite with the primary end point from TASS (nonfatal stroke or death from any cause) and with the secondary end point from TASS (fatal or nonfatal stroke). Data were interpreted using an intent-to-treat analysis. Only the first end point event for a given patient was counted in an end point composite. Cumulative event rates were determined by the Kaplan-Meier method, and overall survival and percent risk reduction were estimated using the Cox model with treatment as a covariate. Differences between treatment groups were compared by means of the Mantel-Haenszel log-rank test.
Results
During enrollment, 3069 patients were randomly assigned to therapy with aspirin or ticlopidine and were included in the intent-to-treat analysis. The baseline demographics and clinical and medical history have been previously reported and are summarized in Table  1 .3 There were no significant differences between ticlopidine and aspirin groups with respect to any baseline characteristic.
The number of first clinical events for the end point of Table 3 . At 1 year, the risk reduction for ticlopidine versus aspirin for reversible ischemic events was 19.8%, for reversible ischemic events plus nonfatal stroke or death was 23.3%, and for reversible ischemic events plus stroke 22.3%. Overall, ticlopidine was superior to aspirin for reducing the risk of reversible ischemic events alone (P=.001) and when combined with death or nonfatal stroke (P<.001) and fatal or nonfatal stroke (P<.001). For each year of the 5-year follow-up, risk reductions were greater with ticlopidine relative to aspirin.
However, based on data from studies of the natural history of stroke and results from this trial, the risk reduction was greatest during the first year of therapy, when patients are at greatest risk for recurrent cerebral ischemic events. Post hoc analysis revealed that TIA was the most frequent recurrent event of ischemic events reported. Therefore, TIA was considered both when it occurred alone and when it occurred as a composite with death or stroke and with fatal or nonfatal stroke.
reversible ischemic events occurring alone and in com- The most frequent adverse experiences were those relating to the digestive system. Diarrhea was reported in 20.4% of ticlopidine-treated patients and in 9.8% of aspirin-treated patients. Diarrhea almost always occurred early in therapy and usually resolved with a temporary reduction in the ticlopidine dose. Only 6% of patients were permanently withdrawn for diarrhea. The second most common adverse experience was rash, which occurred in 11.9% of patients on ticlopidine and in 5.2% of patients on aspirin. The majority of reports of rash occurred within the first 3 months of therapy. Serious gastrointestinal disorders were more common in patients receiving aspirin than in patients receiving ticlopidine. An increased incidence of serious gastrointestinal complaints including pain, gastritis, hemorrhage, and peptic ulcer was reported by the aspirin group.
Clinically, the most important adverse effect reported with ticlopidine was neutropenia. Neutropenia (absolute neutrophil count, < 1200 cells per cubic millimeter) was reported in 35 ticlopidine-treated patients and in 12 aspirin-treated patients. Thirteen cases of severe ticlo-TIA indicates transient ischemic attack; Ml, myocardial pidine-induced neutropenia (absolute neutrophil count, <450 cells per cubic millimeter) occurred within the first 3 months of therapy but resolved rapidly with discontinuation of ticlopidine.
All serious cases occurred within 90 days of beginning therapy with ticlopidine. Neutropenia from ticlopidine is easily detected and readily managed by monitoring the complete blood cell count every 2 weeks during the first 3 months of therapy. If ticlopidine-induced neutropenia occurs, the neutrophil count recovers rapidly with discontinuation of ticlopidine. Early detection with routine complete blood cell count monitoring during the first 3 months of therapy should prevent any adverse outcomes.
Discussion
In the initial report from TASS, ticlopidine was shown to be superior to aspirin for the prevention of atherothrombotic stroke in patients who had recently experienced a transient or mildly persistent episode of cerebral ischemia.3 In this analysis of tertiary end points, namely TIA, AF, or RIND, the overall risk reduction with ticlopidine was also greater than the risk reduction with aspirin. In fact, the risk reductions with ticlopidine relative to aspirin were greater at each year of the 5-year follow-up. The risk reductions with ticlopidine were maintained even when reversible ischemic events were combined with the "hard" end points of death or stroke, and fatal or nonfatal stroke.
Transient ischemic attacks are a well-recognized risk factor for cerebral infarction; the risk of stroke after a TIA ranges from 4% to 8% per year.7 The incidence of TIA in the United States ranges from 116 to 244 per 100 000 population, and much of the variation is due to the dramatic increase in incidence with age.8 Recurrent TIAs were reported in 30% or more of patients followed in the Hospital Frequency Study. 9 Conneally et a19 identified multiple TIAs before entry as the greatest risk factor for recurrent TIAs. Fields et a110 also reported an increased risk of subsequent cerebral ischemic events in the presence of multiple TIAs. The results in this subgroup of patients with reversible ischemic disease, as well as the overall analysis of TASS, suggest that ticlopidine is more effective than aspirin for prevention of recurrent TIAs. Based on the superiority of ticlopidine for reducing the occurrence of reversible ischemic events, ticlopidine would appear to be an effective option for this indication.
